Jornadas SoGOCyL 2016 I JORNADA DE CIRUGIA ONCOLOGICA PERITONEAL Reunión de presentación de la UNIDAD DE REFERENCIA REGIONAL DE CIRUGIA ONCOLOGICA PERITONEAL JORNADAS SoGOCyL 2014
http://www.sogocyl.com/components/com_gk3_photoslide/thumbs_big/977682cabecera_SOGOCYL2015.jpglink
http://www.sogocyl.com/components/com_gk3_photoslide/thumbs_big/795103hosp_01.jpglink
http://www.sogocyl.com/components/com_gk3_photoslide/thumbs_big/544032hosp_02.jpglink
http://www.sogocyl.com/components/com_gk3_photoslide/thumbs_big/402775cabecera_sogocyl2014.jpglink

Jornadas SoGOCyL 2016

Se celebrará la IV Reunión de la Sociedad de Ginecología Oncológica y Patología Mamaria de Castilla y León los días 5, 6 y 7 de Mayo de 2016

I JORNADA DE CIRUGIA ONCOLOGICA PERITONEAL

Se celebra el 25 de Noviembre de 2014 a las 10:00 horas en el Salón de Actos del Hospital Universitario Río Hortega de Valladolid...

Reunión de presentación de la UNIDAD DE REFERENCIA REGIONAL DE CIRUGIA ONCOLOGICA PERITONEAL

Se celebra el 3 de Noviembre de 2014, 17:00 horas en Salón de Actos de la Gerencia Regional de Salud...

JORNADAS SoGOCyL 2014

Se celebrará la III Reunión de la Sociedad de Ginecología Oncológica y Patología Mamaria de Castilla y León los días 8, 9 y 10 de Mayo de 2014...

Inicio

Pocas niñas, adolescentes y mujeres jóvenes se ponen la vacuna contra el virus del papiloma humano (VPH) y muchas de las que inician el régimen no reciben las tres dosis, según revela una investigación reciente.

Aunque estudios han mostrado que la vacuna contra el VPH es segura y eficaz contra varias cepas del virus de transmisión sexual, apenas un tercio de las adolescentes y mujeres jóvenes que inician la serie de tres dosis la completan, y casi tres cuartas partes ni siquiera la comienzan, según una investigación que se presenta esta semana en la reunión anual de la Asociación Estadounidense de Investigación del Cáncer (American Association of Cancer Research) en Filadelfia.

"Entre las mujeres que son elegibles para esta vacuna y que podrían beneficiarse potencialmente, las tasas de vacunación no son suficientes para prevenir al máximo el cáncer de cuello uterino", señaló la autora del estudio J. Kathleen Tracy, profesora asistente de epidemiología y salud pública de la Facultad de medicina de la Universidad de Maryland en Baltimore.

 "Esto resalta la necesidad de promociones de salud pública y patrones de práctica para fomentar la administración de las vacunas, o al menos discutir las ventajas y desventajas", comentó Tracy.

Tracy comenzó un estudio para ver si los mensajes de texto animarán a las muje

 res de 18 a 26 años a cumplir con sus citas de seguimiento para las próximas dosis de la vacuna.

Según la información de respaldo del resumen, alrededor del 30 por ciento de las personas de 14 a 19 años de edad que son sexualmente activas están infectadas con VPH en un momento dado. Con el tiempo, la infección persistente puede llevar a cáncer del cuello uterino.

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

The Lancet, Volume 373, Issue 9658, Pages 125 - 136, 10 January 2009 <Previous Article|Next Article>doi:10.1016/S0140-6736(08)61766-3Cite or Link Using DOI

Published Online: 13 December 2008

The writing committee on behalf of the ASTEC study group‡

Summary

Background

Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the standard surgery for stage I endometrial cancer. Systematic pelvic lymphadenectomy has been used to establish whether there is extra-uterine disease and as a therapeutic procedure; however, randomised trials need to be done to assess therapeutic efficacy. The ASTEC surgical trial investigated whether pelvic lymphadenectomy could improve survival of women with endometrial cancer.

 

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

The Lancet, Volume 373, Issue 9658, Pages 137 - 146, 10 January 2009 <Previous Article|Next Article>doi:10.1016/S0140-6736(08)61767-5Cite or Link Using DOI

Published Online: 13 December 2008

The ASTEC/EN.5 writing committee on behalf of the ASTEC/EN.5 Study Group‡

Summary

Background

Early endometrial cancer with low-risk pathological features can be successfully treated by surgery alone. External beam radiotherapy added to surgery has been investigated in several small trials, which have mainly included women at intermediate risk of recurrence. In these trials, postoperative radiotherapy has been shown to reduce the risk of isolated local recurrence but there is no evidence that it improves recurrence-free or overall survival. We report the findings from the ASTEC and EN.5 trials, which investigated adjuvant external beam radiotherapy in women with early-stage disease and pathological features suggestive of intermediate or high risk of recurrence and death from endometrial cancer.

Methods

Between July, 1996, and March, 2005, 905 (789 ASTEC, 116 EN.5) women with intermediate-risk or high-risk early-stage disease from 112 centres in seven countries (UK, Canada, Poland, Norway, New Zealand, Australia, USA) were randomly assigned after surgery to observation (453) or to external beam radiotherapy (452). A target dose of 40—46 Gy in 20—25 daily fractions to the pelvis, treating five times a week, was specified. Primary outcome measure was overall survival, and all analyses were by intention to treat. These trials were registered ISRCTN 16571884 (ASTEC) and NCT 00002807 (EN.5).

Para-aortic lymphadenectomy in endometrial cancer

Escrito por SoGOCyL Sábado, 01 de Enero de 2011 11:26

Para-aortic lymphadenectomy in endometrial cancer

Lancet, Volume 376, Issue 9740, Pages 511 - 512, 14 August 2010 <Previous Article|Next Article>doi:10.1016/S0140-6736(10)61245-7Cite or Link Using DOI

Clare Griffin a, Ann Marie Swart a, Wendi Qian a, Henry Kitchener b

We were not surprised that the results of the retrospective cohort analysis of SEPAL1 differed from those of two randomised controlled trials.2, 3 With a hazard ratio for overall survival of 1·16 (favouring no lymphadenectomy) in ASTEC,2 it is extremely unlikely that conclusions would change with long-term follow-up because there would have to be a large, late effect which is not suggested by SEPAL. Lymphadenectomy significantly increases moderate and severe morbidity, particularly lymphoedema, and removing more lymph nodes might not be better (figure).

ASTEC effect of lymphadenectomy in centres grouped according to median nodes removed

O-E=observed minus expected. Outer bars show 99% CI, inner bars show 95% CI.

Lack of information about methods makes the results impossible to interpret, particularly patient selection and surgery details (operation length, blood loss, postoperative hospital stay, and related deaths). The median age of 56 years suggests substantial selection (median age was 63 years in ASTEC). Data were gathered over 18 years and information about the distribution of patients in each group across time and any time effect on survival is important. Bias due to differences between the hospitals cannot be excluded, with differing adjuvant protocols and almost double the number of pelvic nodes removed in some hospitals compared with others.

In women at intermediate or high risk of recurrence, the substantial difference in adjuvant chemotherapy received (77% vs 45%) is important. Chemotherapy reduces distal metastases,4 potentially improving survival and the effect of para-aortic lymphadenectomy. The benefit in high-risk patients receiving chemotherapy is only just significant. Since type of lymphadenectomy and adjuvant treatment were independent risk factors for overall survival, there are strong statistical arguments for sensitivity analyses excluding those receiving adjuvant treatment.

Aortic lymphadenectomy was not assessed in either randomised trial and the results of this observational study do not invalidate the conclusions of these trials nor provide conclusive evidence of a real treatment effect.

<< Inicio < Prev 1 2 3 4 5 6 7 8 9 Próximo > Fin >>
Página 8 de 9

IV Jornadas Sogocyl

IV Reunión de la Sociedad de Ginecología Oncológica y Patología Mamaria de Castilla y León

Únete a SoGOCyL

Asociate a SoGOCyL

Acceso

Eventos

« Noviembre 2017 »
Lun Mar Mier Jue Vie Sáb Dom
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Hospitales SACYL

Colaboradores

segosogicyl

sacyl


Servicio de Obstetricia y Ginecología del CAULE, c) Altos de Nava s/n León 24080  -  Tfno.: 987-234900. Ext.: 2277.  -  e-mail: info@sogocyl.com

SoGOCyLMAPA WEBPOLÍTICA DE PRIVACIDADAVISO LEGALCONTACTO